Safety and efficacy of a programmed cell death 1 inhibitor combined with oxaliplatin plus S-1 in patients with Borrmann large type III and IV gastric cancers

Table 3 Clinicopathological results after surgery

Baseline variable	P-SOX group (n = 28)	SOX group (n = 61)	χ2	P value
Surgical approach			0.149	0.700
Laparoscopy	25 (89.29%)	56 (91.80%)
Open	3 (10.71%)	5 (8.20%)
Extent of resection			0.041	0.840
R0	23 (82.14%)	49 (80.33%)
R1	5 (17.86%)	12 (19.67%)
Nerve invasion			0.634	0.426
No	14 (50%)	25 (40.98%)
Yes	14 (50%)	36 (59.01%)
Vessel invasion			0.214	0.644
No	12 (42.86%)	23 (37.70%)
Yes	16 (57.14%)	38 (62.30%)
Harvested lymph nodes				0.354
Median	27.85 ± 10.27	31.45 ± 12.48
Positive lymph nodes				0.254
Median	4.71 ± 5.52	7.04 ± 8.84

SOX: S-1 + oxaliplatin; P-SOX: Programmed cell death 1 + S-1 + oxaliplatin.